Zai Lab Acquires Global Rights to Two GSK Anti-Inflammatory Assets

23:57 EDT 19 Oct 2016 | ChinaBio Today

Zai Lab of Shanghai in-licensed global rights to two anti-inflammatory candidates from GlaxoSmithKline. Zai did not disclose many details about the assets, which target multiple anti-inflammatory indications, except to say that one is in a Phase II trial and the other in pre-clinical development. Zai's rights to the drugs include global commercialization. Zai already has two other molecules for anti-inflammation in clinical development, one targets asthma/COPD, the other targets graft-versus-host/irritable bowel syndrome. More details....

Stock Symbol: (NYSE: GSK)

Share this with colleagues:  

Original Article: Zai Lab Acquires Global Rights to Two GSK Anti-Inflammatory Assets


More From BioPortfolio on "Zai Lab Acquires Global Rights to Two GSK Anti-Inflammatory Assets"

Quick Search

Relevant Topics

GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Asthma is caused by inflammation of small tubes, called bronchi, which carry air in and out of the lungs. If you have asthma, the bronchi will be inflamed and more sensitive than normal.  When you come into contact with something that irritates your...